Insmed is a biopharmaceutical company focused on developing treatments for patients with serious and rare diseases. A key area of its research is Pulmonary Arterial Hypertension (PAH), a type of high blood pressure that affects arteries in the lungs and the right side of the heart. The company is actively developing new therapies to address this condition.
On July 20, 2026, BMO Capital initiated coverage on Insmed with an "Outperform" rating. This suggests the analyst expects the biotech stock to perform better than the overall market. A price target of $192.00 was also set, which is an analyst's estimate of the stock's future value. This target represents a potential 79.41% increase from its price of $107.02 at the time.
This positive outlook is supported by recent clinical news. As highlighted by PR Newswire, Insmed announced positive 12-month data for its PAH treatment, TPIP. The study showed sustained improvement in patients and a strong safety profile. These results strengthen the potential for TPIP to become a preferred treatment option for PAH patients.
However, institutional investor sentiment shows some mixed activity. According to a recent SEC disclosure, Bank of New York Mellon Corp reduced its holdings in Insmed by 9.2% during the first quarter. The firm sold approximately 127,000 shares, leaving it with a position valued at about $206.5 million.
In contrast, other investors have increased their positions. CIBC Private Wealth Group LLC raised its stake by 42.1%, while CoreCap Advisors LLC established a new position valued at around $27,000. Currently, Insmed shares trade between a day low of $106.63 and a day high of $109.43, with a market capitalization of approximately $23.2 billion.
